Ustekinumab

BreastfeedingPediatric
  • TRADE NAME: Stelara (Centocor)
  • INDICATIONS: Plaque psoriasis (moderate to severe); active psoriatic arthritis; active Crohn's disease (moderate to severe)
  • CLASS: Interleukin-12/23 antagonist, Monoclonal antibody
  • HALF-LIFE: 15–32 days
CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:

Live vaccines

PREGNANCY CATEGORY: B

Our database has 61 adverse reactions for this drug across the following areas

Please login to see the rest of this drug profile


Not a subscriber? Click here to subscribe

SKIN
HAIR
MUCOSAL
CARDIOVASCULAR
CENTRAL NERVOUS SYSTEM
NEUROMUSCULAR/SKELETAL
GASTROINTESTINAL/HEPATIC
RESPIRATORY
ENDOCRINE/METABOLIC
HEMATOLOGIC
LOCAL
OTHER


Visit Informa

Click on the DRUG REVIEW ARTICLE tab (above) to see a review of ustekinumab in the Taylor & Francis journal Expert Opinion on Drug Safety. (Note that non-subscribers to the journal will only be able to see an abstract of the article.)

Page last updated 09/27/2018

Drug Eruption Mobile Site

Symbol key

Incidence info

  • <1%
  • 1-5%
  • 5-10%
  • 10-15%
  • 15-20%
  • 20-30%
  • >30%

Seriousness info

  • Hospitalization possible
  • Life threatening
  • Fatal

Warnings in other populations info

  • Breast feeding
  • Geriatric
  • Pediatric